We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Iovance

News List

Cell therapy for solid tumors may get approval by 2022: GlobalData expresspharma
May 06, 2021
A total of 298 industry-sponsored trials are currently ongoing investigating cell therapies in non-haematological cancers, says GlobalData.
Avid Selected to Lead Process Development of IOV-3001 contractpharma
August 10, 2020
Will provide process development, pilot-batch manufacturing & CGMP manufacturing services for Iovance Biotherapeutics.
Iovance Biotherapeutics secures IOV-3001 licencing from Novartis pharmaceutical-technology
January 14, 2020
Iovance Biotherapeutics has secured the licence to develop and commercialise IOV-3001, an antibody cytokine engrafted protein, from Novartis.
Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy drugs
May 30, 2019
Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy.